Safety Concerns Halt Depression Trials; Gen Z and Alcohol; Prescribing Benzos

Xenon Pharmaceuticals said it paused enrollment in its major depressive disorder and bipolar depression trials after unexpected neuropsychiatric adverse events emerged.

Many mental health and suicide risk indicators among youth improved from 2023 to 2025, according to the CDC’s “Youth Health in Focus” report.

Johnson & Johnson’s lumateperone (Caplyta) met its phase III primary endpoint, rapidly reducing acute manic symptoms in bipolar I disorder as early as day 3.

A mother of two detailed her experience with the psychedelic psilocybin as part of a pilot trial to treat Lyme disease. (Washington Post)

Alkermes announced positive phase Ib proof-of-concept data for its investigational orexin 2 receptor agonist, showing clinically meaningful reduction of attention deficit-hyperactivity disorder (ADHD) symptoms in adults.

New phase IIIb trial data for centanafadine (Simtriyo) demonstrated consistent improvements across ADHD and anxiety symptoms, emotional dysregulation, and executive function, said Otsuka Pharmaceutical.

Gen Z and Millennials drove recent drops in alcohol use, a cross-sectional study of National Health Interview Survey data showed. (Annals of Internal Medicine)

Actress Brittany Snow said she “didn’t know if she would make it” when reflecting on her 17-year recovery journey from an eating disorder. (People)

Psychiatrists should explicitly define near-term treatment goals at every visit when prescribing benzodiazepines, experts argued in the American Journal of Psychiatry.

Children as young as 13 are showing up at a U.K. specialty hospital with ketamine-induced uropathy, also referred to as “ketamine bladder,” an analysis of U.K. clinic data found. (Archives of Disease in Childhood)

Without competency in deaf and hard-of-hearing care, psychiatrists risk misinterpreting both patient expression and thought processes, experts warned in a JAMA Psychiatry Viewpoint.